CNS OncologyPub Date : 2024-06-06Epub Date: 2024-03-08DOI: 10.2217/cns-2023-0029
Edina Komlodi-Pasztor, Vasu Munjapara, Charles G Eberhart, Danielle A Bazer, Mohamed R Sherief, David Olayinka Kamson, Xiaobu Ye, Byram Hirsch Ozer, Matthias Holdhoff
{"title":"Postradiation platinum-etoposide in adult medulloblastomas: retrospective analysis of hematological toxicity.","authors":"Edina Komlodi-Pasztor, Vasu Munjapara, Charles G Eberhart, Danielle A Bazer, Mohamed R Sherief, David Olayinka Kamson, Xiaobu Ye, Byram Hirsch Ozer, Matthias Holdhoff","doi":"10.2217/cns-2023-0029","DOIUrl":"10.2217/cns-2023-0029","url":null,"abstract":"<p><p><b>Aim:</b> Adult medulloblastomas (MB) are rare, and optimal post-craniospinal irradiation (CSI) chemotherapy is not yet defined. We investigated hematological toxicity in patients treated with platinum-etoposide (EP) post-CSI. <b>Methods:</b> Retrospective, single-institution study to determine hematological toxicity in adult MB patients treated with EP (1995-2022). <b>Results:</b> Thirteen patients with a median follow-up of 50 months (range, 10-233) were analyzed. Four discontinued treatment due to toxicity, one after 1, 3 after 3 cycles. Hematological toxicities included grade 3 (5 patients) and grade 4 (6 patients). Two patients experienced post-treatment progression and died 16 and 37 months from diagnosis. <b>Conclusion:</b> Post-CSI EP demonstrates acceptable hematological toxicity in adult MB. However, the small cohort precludes definitive survival outcome conclusions. Prospective studies for comprehensive comparisons with other regimens are needed in this context.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":" ","pages":"CNS107"},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11137761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140058866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CNS OncologyPub Date : 2024-06-06Epub Date: 2024-06-12DOI: 10.1080/20450907.2024.2351789
Carlen A Yuen, Melike Pekmezci, Silin Bao, Xiao-Tang Kong
{"title":"Metastatic glioblastoma to the lungs: a case report and literature review.","authors":"Carlen A Yuen, Melike Pekmezci, Silin Bao, Xiao-Tang Kong","doi":"10.1080/20450907.2024.2351789","DOIUrl":"10.1080/20450907.2024.2351789","url":null,"abstract":"<p><p>Glioblastoma is the most common malignant primary brain tumor. Despite its infiltrative nature, extra-cranial glioblastoma metastases are rare. We present a case of a 63-year-old woman with metastatic glioblastoma in the lungs. Sarcomatous histology, a reported risk factor for disseminated disease, was found. Genomic alterations of <i>TP53</i> mutation, <i>TERT</i> mutation, <i>PTEN</i> mutation, and +7/-10 were also uncovered. Early evidence suggests these molecular aberrations are common in metastatic glioblastoma. Treatment with third-line lenvatinib resulted in a mixed response. This case contributes to the growing body of evidence for the role of genomic alterations in predictive risk in metastatic glioblastoma. There remains an unmet need for treatment of metastatic glioblastoma.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"13 1","pages":"2351789"},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11172249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CNS OncologyPub Date : 2024-05-20DOI: 10.1080/20450907.2024.2347824
Toru Imai, H. Shoji, H. Hirano, Kunihito Matsuguma, Takahito Awatsu, T. Hirose, N. Okita, A. Takashima, Ken Kato
{"title":"BRAF\u0000 V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab","authors":"Toru Imai, H. Shoji, H. Hirano, Kunihito Matsuguma, Takahito Awatsu, T. Hirose, N. Okita, A. Takashima, Ken Kato","doi":"10.1080/20450907.2024.2347824","DOIUrl":"https://doi.org/10.1080/20450907.2024.2347824","url":null,"abstract":"","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"42 20","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141118996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}